17:41 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Epizyme falls on DLBCL discontinuations for tazemetostat

Epizyme Inc. (NASDAQ:EPZM) lost $3.10 (24%) to $9.90 on Aug. 2 after discontinuing development of tazemetostat both as monotherapy and in combination with prednisolone to treat diffuse large B cell lymphoma (DLBCL). The news comes...
21:12 , Aug 2, 2018 |  BC Extra  |  Clinical News

Epizyme falls on DLBCL discontinuations for tazemetostat

Epizyme Inc. (NASDAQ:EPZM) lost $3.10 (24%) to $9.90 on Thursday after discontinuing development of tazemetostat both as monotherapy and in combination with prednisolone to treat diffuse large B cell lymphoma. The news comes three months...
17:14 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Constellation raises $60M in NASDAQ IPO

Epigenetics company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised $60 million on July 18 through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital Markets and Oppenheimer....
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
00:51 , Jul 19, 2018 |  BC Extra  |  Financial News

Constellation slips after pricing $60M IPO

Constellation Pharmaceuticals Inc. (NASDAQ:CNST) dipped $3.52 (23%) to $11.48 Thursday after it raised $60 million through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital...
17:40 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting EZH2 or promoting FOXC1 expression could help treat the luminal B subtype of metastatic breast cancer. In patients with luminal B-type breast cancer, low...
17:46 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived metastatic neuroendocrine prostate cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by culturing enzyme-dissociated cells from samples of a patient’s liver, lymph node and...
21:39 , Jun 23, 2018 |  BC Extra  |  Financial News

Latest batch of IPO filings: Rubius, Constellation, Replimune, Allakos

As a busy week for IPO pricings came to a close, several more companies filed for NASDAQ listings late Friday, further stocking an IPO pipeline of companies likely to seek liquidity during a tight calendar...
19:57 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

FDA places clinical hold on Ph I of Epizyme's tazemetostat

Epizyme Inc. (NASDAQ:EPZM) said FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma during a Phase I pediatric trial of the selective...
17:34 , Apr 24, 2018 |  BC Extra  |  Financial News

Epizyme falls on clinical hold

Epizyme Inc. (NASDAQ:EPZM) fell $2.30 (15%) to $13 in afternoon trading Tuesday after reporting late Monday that FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438). The move shaved $160 million off the company’s...